Diabetes Drug Actos Linked to Bladder Cancer
September 14, 2011, by JONES WARD PLC
In June of this year, the FDA announced that use of the diabetes drug Actos may be associated with a greater risk of bladder cancer. Based on its findings from the first five years of a ten-year study, the FDA recommended that Actos not be prescribed in patients with a history of bladder cancer or with active bladder cancer.
Actos has been used to control type 2 diabetes in adults. In the first ten months of 2010 alone, 2.3 million patients filled prescriptions for Actos or other drugs containing pioglitazone. Takeda Pharmaceuticals Co. Ltd., the maker of Actos, is already facing hundreds of lawsuits over the drug.
Continue reading "Diabetes Drug Actos Linked to Bladder Cancer" »
